Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 50971-50973 [E7-17511]

Download as PDF 50971 Federal Register / Vol. 72, No. 171 / Wednesday, September 5, 2007 / Notices Estimated Total Annual Burden Hours: 9,880. In compliance with the requirements of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L’Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. E-mail address: infocollection@acf.hhs.gov. All requests should be identified by the title of the information collection. The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication. Dated: August 28, 2007. Janean Chambers, Reports Clearance Officer. [FR Doc. 07–4310 Filed 9–4–07; 8:45 am] BILLING CODE 4184–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Submission for OMB Review; Comment Request Title: Title V section 510 Abstinence Education Grant Program—Annual Program Application and Annual Performance Progress Report. OMB No.: 0970–0271. Description: The Title V section 510 Abstinence Education Grant Program (section 510 program) is a formula block grant program, authorized through September 30, 2007, by S. 1701, a bill to provide for the extension of transitional medical assistance (TMA) and the abstinence education program through the end of fiscal year 2007, and for other purposes. The section 510 Annual Program Application requires basic application information that will be used by the Administration for Children and Families (ACF) to establish applicant eligibility, determine each applicant’s compliance with Federal law, review and evaluate each applicant’s proposed plans, and to develop any conditions to be placed on grant awards. Projects must meet the legislative priorities as described in section 510 of Title V of the Social Security Act. The section 510 Annual Performance Progress Report includes four forms through which grantees report basic performance information, which is used by ACF to determine each grantee’s compliance with Federal law and to review and evaluate each applicant’s progress toward achieving its goals. Basic performance information includes the unduplicated count of clients served, hours of service received by clients, program completion data, and communities served. Respondents: The 50 States, the District of Columbia, and the following 8 Territories: American Samoa, Guam, Republic of the Marshall Islands, Federated States of Micronesia, Commonwealth of the Northern Mariana Islands, Republic of Palau, Commonwealth of Puerto Rico, and the U.S. Virgin Islands. ANNUAL BURDEN ESTIMATES Number of respondents Instrument rfrederick on PROD1PC67 with NOTICES Annual Program Application ............................................................................ Annual Performance Progress Report ............................................................. Estimated Total Annual Burden Hours: 9,322. Additional Information: Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Administration, Office of Information Services, 370 L’Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection. E-mail address: infocollection@acf.hhs.gov. OMB Comment: OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should VerDate Aug<31>2005 13:51 Sep 04, 2007 Jkt 211001 59 59 be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Fax: 202–395–6974. Attn: Desk Officer for the Administration for Children and Families. Dated: August 29, 2007. Janean Chambers, Reports Clearance Officer. [FR Doc. 07–4311 Filed 9–4–07; 8:45 am] BILLING CODE 4184–01–M PO 00000 Response per respondent Average burden hours per response 1 1 Total burden hours 36 122 2,124 7,198 DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS. AGENCY: ACTION: Notice. SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first Frm 00041 Fmt 4703 Sfmt 4703 E:\FR\FM\05SEN1.SGM 05SEN1 rfrederick on PROD1PC67 with NOTICES 50972 Federal Register / Vol. 72, No. 171 / Wednesday, September 5, 2007 / Notices published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644). A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory’s certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter. This notice is also available on the Internet at https:// www.workplace.samhsa.gov and https:// www.drugfreeworkplace.gov. FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, SAMHSA/CSAP, Room 2–1035, 1 Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276– 2610 (fax). SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100– 71. Subpart C of the Mandatory Guidelines, ‘‘Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies,’’ sets strict standards that laboratories must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards. In accordance with Subpart C of the Mandatory Guidelines dated April 13, 2004 (69 FR 19644), the following laboratories meet the minimum standards to conduct drug and specimen validity tests on urine specimens: ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328– VerDate Aug<31>2005 13:51 Sep 04, 2007 Jkt 211001 7840/800–877–7016 (Formerly: Bayshore Clinical Laboratory). ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264. Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770/888–290– 1150. Aegis Sciences Corporation, 345 Hill Ave., Nashville, TN 37210, 615–255– 2400 (Formerly: Aegis Analytical Laboratories, Inc.). Baptist Medical Center-Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–202–2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center). Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215–2802, 800– 445–6917. Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 239–561–8200/800–735– 5416. Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229–671– 2281. DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974, 215–674–9310. Dynacare Kasper Medical Laboratories,* 10150–102 St., Suite 200, Edmonton, Alberta, Canada T5J 5E2, 780–451– 3702 / 800–661–9876. ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662– 236–2609. Gamma-Dynacare Medical Laboratories,* A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519– 679–1630. Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504– 361–8989 / 800–433–3823 (Formerly: Laboratory Specialists, Inc.). Kroll Laboratory Specialists, Inc., 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130 (Formerly: Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.). Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288 / 800–800–2387. Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400 / 800–437–4986 (Formerly: Roche Biomedical Laboratories, Inc.). Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919–572–6900 / 800–833–3984 (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group). Laboratory Corporation of America Holdings, 13112 Evening Creek Drive, Suite 100, San Diego, CA 92128, 858– 668–3710 / 800–882–7272 (Formerly: Poisonlab, Inc.). Laboratory Corporation of America Holdings, 550 17th Ave., Suite 300, Seattle, WA 98122, 206–923–7020 / 800–898–0180 (Formerly: DrugProof, Division of Dynacare/Laboratory of Pathology, LLC; Laboratory of Pathology of Seattle, Inc.; DrugProof, Division of Laboratory of Pathology of Seattle, Inc.). Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827–8042 / 800–233–6339 (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center). LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927 / 800–873–8845 (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.). Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715– 389–3734 / 800–331–3734. MAXXAM Analytics Inc.*, 6740 Campobello Road, Mississauga, ON, Canada L5N 2L8, 905–817–5700 (Formerly: NOVAMANN (Ontario), Inc.). MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 651–636–7466 / 800–832–3244. Meriter Laboratories, 36 South Brooks St., Madison, WI 53715, 608–267– 6225, (Formerly: General Medical Laboratories). MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295 / 800–950– 5295. Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725– 2088. National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250 / 800–350– 3515. One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888–747–3774 (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory). E:\FR\FM\05SEN1.SGM 05SEN1 rfrederick on PROD1PC67 with NOTICES Federal Register / Vol. 72, No. 171 / Wednesday, September 5, 2007 / Notices Oregon Medical Laboratories, 123 International Way, Springfield, OR 97477, 541–341–8092. Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–328–6942 (Formerly: Centinela Hospital Airport Toxicology Laboratory). Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509–755–8991 / 800–541–7891x7. Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858–643– 5555. Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913–339–0372 / 800–821– 3627. Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, 770–452–1590 / 800–729–6432 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline BioScience Laboratories). Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610–631–4600 / 877–642–2216 (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline BioScience Laboratories). Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, 866–370–6699/818–989–2521 (Formerly: SmithKline Beecham Clinical Laboratories). S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505– 727–6300/800–999–5227. South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574–234–4176 x276. Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040, 602–438–8507/800–279– 0027. Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, 517–364–7400 (Formerly: St. Lawrence Hospital & Healthcare System). St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405–272– 7052. Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 573–882–1273. Toxicology Testing Service, Inc., 5426 NW. 79th Ave., Miami, FL 33166, 305–593–2260. U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755– 5235, 301–677–7085. VerDate Aug<31>2005 13:51 Sep 04, 2007 Jkt 211001 *The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 13, 2004 (69 FR 19644). After receiving DOT certification, the laboratory will be included in the monthly list of HHScertified laboratories and participate in the NLCP certification maintenance program. Elaine Parry, Acting Director, Office of Program Services, SAMHSA. [FR Doc. E7–17511 Filed 9–4–07; 8:45 am] BILLING CODE 4160–20–P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR–5121–N–27] Notice of Proposed Information Collection: Comment Request; Continuation of Interest Reduction Payments After Refinancing Section 236 Projects Office of the Assistant Secretary for Housing-Federal Housing Commissioner, HUD. ACTION: Notice. AGENCY: SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal. DATES: Comments Due Date: November 5, 2007. PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 50973 Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Lillian Dietzer, Reports Management Officer, Department of Housing and Urban Development, 451 7th Street, SW., L’Enfant Plaza Building, Room 8001, Washington, DC 20410 or Lillian_L_Dietzer@hud.gov. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Kimberly R. Munson, Housing Program Manager, Office of Asset Management, Department of Housing and Urban Development, 451 7th Street, SW., Washington, DC 20410, telephone (202) 708–1320 (this is not a toll free number) for copies of the proposed forms and other available information. SUPPLEMENTARY INFORMATION: The Department is submitting the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended). This Notice is soliciting comments from members of the public and affected agencies concerning the proposed collection of information to: (1) Evaluate whether the proposed collection is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information; (3) enhance the quality, utility, and clarity of the information to be collected; and (4) minimize the burden of the collection of information on those who are to respond; including the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. This Notice also lists the following information: Title of Proposal: Continuation of Interest Reduction Payments after Refinancing Section 236 Projects. OMB Control Number, if applicable: 2502–NEW. Description of the need for the information and proposed use: The purpose of this information collection is to preserve low-income housing units. HUD uses the information to ensure that owners and mortgagees/public entities enter into binding agreements for continuation of Interest Reduction Payments (IRP) after refinancing certain Section 236 projects. Agency form numbers, if applicable: None. Estimation of the total numbers of hours needed to prepare the information collection including number of E:\FR\FM\05SEN1.SGM 05SEN1

Agencies

[Federal Register Volume 72, Number 171 (Wednesday, September 5, 2007)]
[Notices]
[Pages 50971-50973]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-17511]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Current List of Laboratories Which Meet Minimum Standards To 
Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services (HHS) notifies 
Federal agencies of the laboratories currently certified to meet the 
standards of Subpart C of the Mandatory Guidelines for Federal 
Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory 
Guidelines were first

[[Page 50972]]

published in the Federal Register on April 11, 1988 (53 FR 11970), and 
subsequently revised in the Federal Register on June 9, 1994 (59 FR 
29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 
FR 19644).
    A notice listing all currently certified laboratories is published 
in the Federal Register during the first week of each month. If any 
laboratory's certification is suspended or revoked, the laboratory will 
be omitted from subsequent lists until such time as it is restored to 
full certification under the Mandatory Guidelines.
    If any laboratory has withdrawn from the HHS National Laboratory 
Certification Program (NLCP) during the past month, it will be listed 
at the end, and will be omitted from the monthly listing thereafter.
    This notice is also available on the Internet at https://
www.workplace.samhsa.gov and https://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, 
Division of Workplace Programs, SAMHSA/CSAP, Room 2-1035, 1 Choke 
Cherry Road, Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-
2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in 
accordance with Executive Order 12564 and section 503 of Pub. L. 100-
71. Subpart C of the Mandatory Guidelines, ``Certification of 
Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets 
strict standards that laboratories must meet in order to conduct drug 
and specimen validity tests on urine specimens for Federal agencies. To 
become certified, an applicant laboratory must undergo three rounds of 
performance testing plus an on-site inspection. To maintain that 
certification, a laboratory must participate in a quarterly performance 
testing program plus undergo periodic, on-site inspections.
    Laboratories which claim to be in the applicant stage of 
certification are not to be considered as meeting the minimum 
requirements described in the HHS Mandatory Guidelines. A laboratory 
must have its letter of certification from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met minimum standards.
    In accordance with Subpart C of the Mandatory Guidelines dated 
April 13, 2004 (69 FR 19644), the following laboratories meet the 
minimum standards to conduct drug and specimen validity tests on urine 
specimens:

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-
7840/800-877-7016 (Formerly: Bayshore Clinical Laboratory).
ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 
585-429-2264.
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, 
TN 38118, 901-794-5770/888-290-1150.
Aegis Sciences Corporation, 345 Hill Ave., Nashville, TN 37210, 615-
255-2400 (Formerly: Aegis Analytical Laboratories, Inc.).
Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7, 
Little Rock, AR 72205-7299, 501-202-2783 (Formerly: Forensic Toxicology 
Laboratory Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 800-
445-6917.
Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, 
FL 33913, 239-561-8200/800-735-5416.
Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229-
671-2281.
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974, 
215-674-9310.
Dynacare Kasper Medical Laboratories,\*\ 10150-102 St., Suite 200, 
Edmonton, Alberta, Canada T5J 5E2, 780-451-3702 / 800-661-9876.
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 
662-236-2609.
Gamma-Dynacare Medical Laboratories,\*\ A Division of the Gamma-
Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, 
Canada N6A 1P4, 519-679-1630.
Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 
504-361-8989 / 800-433-3823 (Formerly: Laboratory Specialists, Inc.).
Kroll Laboratory Specialists, Inc., 450 Southlake Blvd., Richmond, VA 
23236, 804-378-9130 (Formerly: Scientific Testing Laboratories, Inc.; 
Kroll Scientific Testing Laboratories, Inc.).
Laboratory Corporation of America Holdings, 7207 N. Gessner Road, 
Houston, TX 77040, 713-856-8288 / 800-800-2387.
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 
08869, 908-526-2400 / 800-437-4986 (Formerly: Roche Biomedical 
Laboratories, Inc.).
Laboratory Corporation of America Holdings, 1904 Alexander Drive, 
Research Triangle Park, NC 27709, 919-572-6900 / 800-833-3984 
(Formerly: LabCorp Occupational Testing Services, Inc., CompuChem 
Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche 
Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of 
the Roche Group).
Laboratory Corporation of America Holdings, 13112 Evening Creek Drive, 
Suite 100, San Diego, CA 92128, 858-668-3710 / 800-882-7272 (Formerly: 
Poisonlab, Inc.).
Laboratory Corporation of America Holdings, 550 17th Ave., Suite 300, 
Seattle, WA 98122, 206-923-7020 / 800-898-0180 (Formerly: DrugProof, 
Division of Dynacare/Laboratory of Pathology, LLC; Laboratory of 
Pathology of Seattle, Inc.; DrugProof, Division of Laboratory of 
Pathology of Seattle, Inc.).
Laboratory Corporation of America Holdings, 1120 Main Street, 
Southaven, MS 38671, 866-827-8042 / 800-233-6339 (Formerly: LabCorp 
Occupational Testing Services, Inc.; MedExpress/National Laboratory 
Center).
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 
66219, 913-888-3927 / 800-873-8845 (Formerly: Quest Diagnostics 
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division 
of LabOne, Inc.).
Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak 
Ave., Marshfield, WI 54449, 715-389-3734 / 800-331-3734.
MAXXAM Analytics Inc.*, 6740 Campobello Road, Mississauga, ON, Canada 
L5N 2L8, 905-817-5700 (Formerly: NOVAMANN (Ontario), Inc.).
MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 
651-636-7466 / 800-832-3244.
Meriter Laboratories, 36 South Brooks St., Madison, WI 53715, 608-267-
6225, (Formerly: General Medical Laboratories).
MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 
97232, 503-413-5295 / 800-950-5295.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology 
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave., 
Bakersfield, CA 93304, 661-322-4250 / 800-350-3515.
One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, 
TX 77504, 888-747-3774 (Formerly: University of Texas Medical Branch, 
Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).

[[Page 50973]]

Oregon Medical Laboratories, 123 International Way, Springfield, OR 
97477, 541-341-8092.
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 
91311, 800-328-6942 (Formerly: Centinela Hospital Airport Toxicology 
Laboratory).
Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, 
WA 99204, 509-755-8991 / 800-541-7891x7.
Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858-
643-5555.
Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 
66210, 913-339-0372 / 800-821-3627.
Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 
30340, 770-452-1590 / 800-729-6432 (Formerly: SmithKline Beecham 
Clinical Laboratories; SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 
610-631-4600 / 877-642-2216 (Formerly: SmithKline Beecham Clinical 
Laboratories; SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, 
866-370-6699/818-989-2521 (Formerly: SmithKline Beecham Clinical 
Laboratories).
S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 
505-727-6300/800-999-5227.
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South 
Bend, IN 46601, 574-234-4176 x276.
Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177, 
Phoenix, AZ 85040, 602-438-8507/800-279-0027.
Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 
1210 W. Saginaw, Lansing, MI 48915, 517-364-7400 (Formerly: St. 
Lawrence Hospital & Healthcare System).
St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma 
City, OK 73101, 405-272-7052.
Toxicology & Drug Monitoring Laboratory, University of Missouri 
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 
65203, 573-882-1273.
Toxicology Testing Service, Inc., 5426 NW. 79th Ave., Miami, FL 33166, 
305-593-2260.
U.S. Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., 
Fort George G. Meade, MD 20755-5235, 301-677-7085.

    *The Standards Council of Canada (SCC) voted to end its Laboratory 
Accreditation Program for Substance Abuse (LAPSA) effective May 12, 
1998. Laboratories certified through that program were accredited to 
conduct forensic urine drug testing as required by U.S. Department of 
Transportation (DOT) regulations. As of that date, the certification of 
those accredited Canadian laboratories will continue under DOT 
authority. The responsibility for conducting quarterly performance 
testing plus periodic on-site inspections of those LAPSA-accredited 
laboratories was transferred to the U.S. HHS, with the HHS' NLCP 
contractor continuing to have an active role in the performance testing 
and laboratory inspection processes. Other Canadian laboratories 
wishing to be considered for the NLCP may apply directly to the NLCP 
contractor just as U.S. laboratories do.
    Upon finding a Canadian laboratory to be qualified, HHS will 
recommend that DOT certify the laboratory (Federal Register, July 16, 
1996) as meeting the minimum standards of the Mandatory Guidelines 
published in the Federal Register on April 13, 2004 (69 FR 19644). 
After receiving DOT certification, the laboratory will be included in 
the monthly list of HHS-certified laboratories and participate in the 
NLCP certification maintenance program.

Elaine Parry,
Acting Director, Office of Program Services, SAMHSA.
 [FR Doc. E7-17511 Filed 9-4-07; 8:45 am]
BILLING CODE 4160-20-P